Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
- Conditions
- Interventions
- First Posted Date
- 2003-10-09
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 50
- Registration Number
- NCT00003907
- Locations
- 🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
🇺🇸Borgess Medical Center, Kalamazoo, Michigan, United States
Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix
- Conditions
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006482
- Locations
- 🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
🇺🇸Tufts University School of Medicine, Boston, Massachusetts, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
- First Posted Date
- 2003-10-08
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 73
- Registration Number
- NCT00006012
- Locations
- 🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸Siouxland Regional Cancer Center, Sioux City, Iowa, United States
🇺🇸St. Elizabeth Regional Medical Center, Lincoln, Nebraska, United States
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Theradex
- Registration Number
- NCT00069966
- Locations
- 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇺🇸Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, United States
Induction Chemotherapy Using Cyclophosphamide and Topotecan in Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplantation for Newly Diagnosed or Progressive Neuroblastoma
- Conditions
- Interventions
- Biological: filgrastimDrug: cisplatinDrug: cyclophosphamideDrug: doxorubicin hydrochlorideDrug: etoposideDrug: isotretinoinDrug: melphalanDrug: topotecan hydrochlorideDrug: vincristine sulfateProcedure: conventional surgeryProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT00070200
- Locations
- 🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
🇦🇺Westmead Hospital, Westmead, New South Wales, Australia
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 43
- Registration Number
- NCT00069953
- Locations
- 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸Hubert H. Humphrey Cancer Center at North Memorial Medical Center, Robbinsdale, Minnesota, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-10-06
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 195
- Registration Number
- NCT00069875
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician, Montreal, Quebec, Canada
🇪🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain
Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-30
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT00003930
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Huntsville Hospital System, Huntsville, Alabama, United States
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
- Conditions
- First Posted Date
- 2003-09-18
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT00002559
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2014-12-25
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 13
- Registration Number
- NCT00068549
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.